Valion Bio, Inc. · NASDAQ:VBIO
Valion Bio — Tivic Health Systems — Investor Presentation (April 2022)
24 slides from Valion Bio's investor presentation, Apr 18, 2022
Slide 1: April 2022 Investor Presentation: Electrons as Medicine
1 2022 APRIL INVESTOR PRESENTATION NASDAQ: TIVC Electrons as Medicine TARGETING INFLAMMATORY RESPONSES WITH BIOELECTRONIC MEDICINE
Slide 2: Forward-looking statements
2 This presentation contains forward - looking statements . All statements other than statements of historical facts contained in this presentation may be forward - looking statements . Statements regarding our future results of operations and financial position, economic performance, business strat
Slide 3: Investment Highlights
3 Investment Highlights TIVIC HEALTH: FOUNDED 2016 30,000 Units Sold 2 FDA Clearances + CE Mark Over 2 3 5 18 500 + IPO PEER - REVIEWED PUBLICATIONS REGULATORY CLEARANCES ISSUED PATENTS PATENTS PENDING 4 - AND 5 - STAR PRODUCT REVIEWS NOVEMBER 2021 Growth company in emerging area of noninvasive bioe
Slide 4: The Big Idea: electrons can be used as medicine
4 THE BIG IDEA The body is an electro chemical system. Electrons can be used as medicine. Bioelectronic medicine treats disease by tuning the electrical signals carried along the neural (nerve) pathways. 4 Bioelectronic medicine “represents a multibillion dollar opportunity, … [and has the] potentia
Slide 5: Moving from implants to non-invasive
5 Moving from implants to non - invasive 1960s Pacemakers 2010s Sleep Apnea, Rheumatoid Arthritis 1990s Deep Brain, Spinal Cord 2020s Non - Invasive Bioelectronics • Bioelectronics historically required implanted, invasive technology • Tivic Health has delivered non - invasive ways to tune neural si
Slide 6: Tivic Health's first platform for non-invasive nerve stimulation
6 TIVIC HEALTH’S FIRST PLATFORM FOR Non - invasive Nerve Stimulation Programmable Parameters produce varied biological responses for different diseases and conditions Patented Form Factor enables low - level electrical current to penetrate deeply through tissue Proprietary Algorithms detect optimal
Slide 7: Robust foundations: IP, clearances, publications
7 K182025 CE 704687 DEN200006 ISSUED PATENTS (issued in 2020 & 2021) 5 PATENTS PENDING 18 STRONG INTELLECTUAL PROPERTY THREE REGULATORY CLEARANCES PEER - REVIEWED PUBLICATIONS Open - label study. Continuous reduction in pain and congestion over 4 - weeks of at - home use. Published: Bioelectronic Me
Slide 8: Product & Pipeline
8 PRODUCT & PIPELINE Other Potential Use Cases Postoperative Pain following sinus surgery 600,000 FESS (sinus) surgeries annually in US, alternative to opioids Temporomandibular Joint Disorder (TMJ) Tinnitus Trigeminal Neuralgia Otitis Media / Ear Infection Migraine Headache 39M people in US, 1B peo
Slide 9: ClearUP: clears congestion, stops sinus pain, non-invasively
9 Clears congestion, stops sinus pain, non - invasively. ClearUP ® • User glides tip along facial skin around cheek, nose, brow (sinus regions) for 5 minutes, twice daily and as needed • Low - level pulsed current flows from tip, through sinus passages • Launched late 2019, winner of numerous innova
Slide 10: Large Markets, Significant Growth Opportunity
10 2019 Sinus Pain from allergies 2021 Moderate to Severe Congestion from any cause 50M monthly allergy sufferers. 1 90% experience sinus pain from allergic rhinitis. 2 27% would consider purchase @ $149. 2 = $1.8B US Market 2 200M US adults experience at least monthly. 1 27% would consider purchase
Slide 11: Competitive landscape: OTC drugs dominate sinus care
11 Oral & Intranasal Decongestants Antihistamines • Treat itchiness • Not effective for congestion and pain • Headache, sleepiness, fatigue, dry mouth, and sore throat • Insomnia, nervousness, heart palpitations, headache, sweating, nausea, trembling, weakness, rebound Saline Irrigation • Messy / im
Slide 12: Strong consumer preference
12 82% preferred ClearUP to existing treatments 1 STRONG CONSUMER PREFERENCE • No pills, no sprays, nothing in the nose • No drugs, no significant side effects reported 2 • Use any time, anywhere, whenever and as often as needed (2) Most common side effect: 0.02% reported mild skin irritation in cli
Slide 13: Fast-acting: double-blind randomized trial
13 Maul XA, Borchard NA, Hwang PH, Nayak JV. Microcurrent technology for rapid relief of sinus pain: a randomized, placebo-controll ed, double-blinded clinical trial. Int Forum Allergy Rhinol. 2019;9:352 – 356. Fast - acting Double - blind, randomized, sham - controlled trial examined acute response
Slide 14: Continued improvement with regular use
14 Goldsobel, A.B., Prabhakar, N. & Gurfein, B.T. Prospective trial examining safety and efficacy of microcurrent stimulation fo r t he treatment of sinus pain and congestion. Bioelectron Med 5, 18 (2019) doi:10.1186/s42234 - 019 - 0035 - x #p < 0.01; *p < 0.0001; two - tailed paired t - test compar
Slide 15: Multiple pathways relieve multiple symptoms
15 Multiple pathways relieve multiple symptoms 1 . Maul, Ximena A . , et al . "Microcurrent technology for rapid relief of sinus pain : a randomized, placebo-controlled, double-blinded clinical trial . " International forum of allergy & rhinology . Vol . 9 . No . 4 . 2019 . Trigeminal nerve activati
Slide 16: Omnichannel, multi-touchpoint approach
16 Tried - and - true omnichannel, multi - touchpoint approach DEMAND GENERATION BUILD CREDIBILITY / RETARGETTING 4 - & 5 - star reviews, clinical publications, value - added content (video content, blogs) DRIVE PURCHASE On - site advertising, co - operative marketing, seasonal promotions GENERATE A
Slide 17: Market development
17 2023+: Additional Channel Growth Opportunity 2022: Optimize and scale highest margin channels MARKET DEVELOPMENT Early Traction Expedited Development Sept 2016 – Sept 2019 2020 - 2021 2022+ • Optimizing website and D2C channels • Scaling - up advertising to drive sales, capture market share • Exp
Slide 18: Financials: operating results
18 Twelve Months Ended December 31 (in thousands) FY 2021 FY 2020 Revenues $ 1,166 $ 860 Direct to consumer 691 551 Retail 591 415 Returns & Warranty Reserves (117) (106) Cost of Sales 1,295 1,085 Variable 1,039 737 Fixed 256 348 Gross Profit (Loss) (129) (225) Operating Profit (Loss) (5,632) (3,204
Slide 19: Share structure and cash
19 Common Stock (outstanding at IPO) 9,715,234 Options and warrants 879,899 Fully Diluted Shares 10,595,133 Single class of shares FINANCIALS • $13M cash at the end of 2021 • No debt • IPO November 2021 to broaden investor reach, build consumer engagement and sales infrastructure and broaden product
Slide 20: 2022 Directions: investing for growth
20 2022 Directions INVESTING FOR GROWTH Broaden ClearUP market penetration • Upgrade ecommerce infrastructure, online website design and branding • Optimize and expand advertising and public relations • Increase support for social media and digital Improve ClearUP gross margin • Increase % of sales
Slide 21: Experienced, execution-oriented leadership
21 Experienced, Execution - oriented Leadership LEADERSHIP TEAM Jennifer Ernst Chief Executive Officer, Co - founder, MBA Built Tivic Health from founding to IPO in 5 years. Took prior company (Thin Film Electronics) from 8 - person R&D team to $480MM market cap in < 5 years, as CEO of US subsidiary
Slide 22: Experienced Board of Directors
22 Experienced Board of Directors Dean Zikria Global Strategy, J&J, Pfizer, Allergy/Asthma Chief Commercial Officer, Intuity Medical. Commercial leadership Pfizer, J&J. Healthcare Strategy at Accenture, Deloitte. Growth leadership in Asthma & Allergy. MBA, Rutgers. BS, Biology, Rutgers. Karen Drexle
Slide 23: Summary
23 Summary TIVIC HEALTH FDA - cleared product in high - growth sector. Established Tier 1 channels growing. Large available market. Clinical validation with leading institutions, peer - reviewed publications. Regulatory clearances for both US and international sales. Robust IP portfolio, recently is
Slide 24: Jennifer Ernst, CEO, Tivic Health
24 24 Jennifer Ernst CEO, Tivic Health jennifer.ernst@tivichealth.com
Tivic Health Systems — Investor Presentation (April 2022) on 6ix